Article Details
Retrieved on: 2024-12-28 13:32:13
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article highlights pharmaceutical giants Eli Lilly and Novo Nordisk, emphasizing their advancements in diabetes treatment and obesity therapy, specifically using peptide therapeutics like GLP-1 receptor agonists semaglutide and tirzepatide. Both companies' innovations and growth make them reliable long-term investment opportunities.
Article found on: www.theglobeandmail.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here